Generic Drug Patient Education: The Complete Playbook for Pharma Teams, Payers, and Health Systems
Executive Summary Generic drugs now account for roughly 90% of all U.S. prescriptions filled, yet constitute less than 13% of […]
Japan Generic Drug Development: The Complete Strategic and Regulatory Playbook for IP Teams, R&D Leads, and Institutional Investors
A deep-dive for pharma/biotech IP strategists, pipeline analysts, and buy-side investors. Part I: The Japanese Pharmaceutical Market Sizing Up the
Generic Drugs Save America $445 Billion a Year. Here’s Why the Model Is Cracking.
The pharmacy counter is one of the most consequential decision points in American healthcare. A prescription that a physician deemed
Generic Drugs Save America $445 Billion a Year. Here’s Why the Model Is Cracking. Read Post »
Drug Patent Portfolio Strategy: The Complete Playbook for Market Exclusivity, IP Valuation, and Competitive Defense
Who this is for: Pharma and biotech IP teams, portfolio managers, R&D leads, M&A counsel, and institutional investors with exposure
Drug Patent Prosecution: The Complete Strategic Playbook for Pharma IP Teams
Section I: The Economic Architecture of Pharmaceutical Patents The 20-Year Fiction: Why Statutory Term and Commercial Life Are Two Different
Drug Patent Prosecution: The Complete Strategic Playbook for Pharma IP Teams Read Post »
Google Patents for Drug IP: The Free Tool That Creates Billion-Dollar Blind Spots
Who this is for: Pharma and biotech IP counsel, portfolio managers, R&D leads, generic drug strategy teams, business development executives,
Google Patents for Drug IP: The Free Tool That Creates Billion-Dollar Blind Spots Read Post »
How to Evaluate CDMO Performance: The Definitive Playbook for Pharma IP Teams, R&D Leads, and Institutional Investors
A comprehensive framework covering due diligence, KPI architecture, IP asset valuation, technology roadmaps, and strategic governance across the full drug
In-Licensing Branded Drugs: The Definitive IP Durability Playbook for Pharma Deal-Makers
When generic competition arrives, it arrives fast. Within the first 12 months of a major brand losing exclusivity, generic entrants
In-Licensing Branded Drugs: The Definitive IP Durability Playbook for Pharma Deal-Makers Read Post »
Generic Drug Market: Why the Cheapest Medicine is Becoming the Most Expensive Problem
I. Executive Summary and Investment Thesis The Core Problem The generic drug industry saves the U.S. healthcare system roughly $216
Generic Drug Market: Why the Cheapest Medicine is Becoming the Most Expensive Problem Read Post »
